References

  1. Ahn J.H. et al, Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19. Journal of Clinical Investigation, 2021; 131 (13) DOI: 10.1172/JCI148517 (viewed 02.07.2021).
  2. Based on nonclinical experiments in a human airway epithelium cell model, prophylactic treatment with Bentrio reduced the viral load of SARS-CoV-2 by 99.4%. No clinical data with Bentrio have been generated so far in Covid-19. Pre-print at Fais, F. et al., Drug-free nasal spray as a barrier against SARS-CoV-2 infection: safety and efficacy in human nasal airway epithelia, bioRxiv 2021.07.12.452021; https://doi.org/10.1101/2021.07.12.452021.
  3. Based on preclinical prophylaxis and exposure studies.
  4. ECDC European Center of Prevention and Diseases Control: https://www.ecdc.europa.eu/en/covid-19/questions-answers/questions-answers-basic-facts (viewed 10.07.2021).
  5. WHO World Health Organization: https://www.who.int/health-topics/coronavirus#tab=tab_3 (viewed 10.07.2021).
  6. AAFA Allergy and Asthma Foundation of America, https://www.aafa.org/allergies.aspx (viewed 10.07.2021).
  7. Nehrig J. et al; Efficacy and safety of a drug-free, barrier-forming nasal spray for allergic rhinitis: randomized, open-label, crossover noninferiority trial: https://www.medrxiv.org/content/10.1101/2021.08.02.21261374v1 (viewed 05.10.2021)

This website uses cookies.

By clicking on the “I accept” button, you consent to our use of cookies as described in our Privacy Notice.

Please choose a language

English
English
English
English
English
English
English
English
English